PURPOSE: Peroxisome proliferator-activated receptor gamma (PPARgamma) is a transcription factor that regulates immune and inflammatory responses. Our laboratory has shown that normal and malignant B cells, including multiple myeloma, express PPARgamma. Moreover, certain PPARgamma ligands can induce apoptosis in multiple myeloma cells. Because PPARgamma ligands can also have PPARgamma-independent effects, the role of PPARgamma in B-cell malignancies remains poorly understood. To further understand the role of PPARgamma, we examined the functional consequences of its overexpression in human multiple myeloma. EXPERIMENTAL DESIGN: In the present work, we developed a lentiviral vector for PPARgamma gene delivery. We transduced multiple myeloma cells with a lentivirus-expressing PPARgamma and studied the involvement of this receptor on cell growth and viability. RESULTS: PPARgamma overexpression decreased multiple myeloma cell proliferation and induced spontaneous apoptosis even in the absence of exogenous ligand. These PPARgamma-overexpressing cells were dramatically more sensitive to PPARgamma ligand-induced apoptosis compared with uninfected or LV-empty-infected cells. Apoptosis was associated with the down-regulation of antiapoptotic proteins X-linked inhibitor of apoptosis protein and myeloid cell leukemia-1 as well as induction of caspase-3 activity. Importantly, PPARgamma overexpression-induced cell death was not abrogated by coincubation with bone marrow stromal cells (BMSC), which are known to protect multiple myeloma cells from apoptosis. Additionally, PPARgamma overexpression in multiple myeloma or BMSC inhibited both basal and multiple myeloma-induced interleukin-6 production by BMSC. CONCLUSIONS: Our results indicate that PPARgamma negatively controls multiple myeloma growth and viability in part through inhibition of interleukin-6 production by BMSC. As such, PPARgamma is a viable therapeutic target in multiple myeloma.
PURPOSE:Peroxisome proliferator-activated receptor gamma (PPARgamma) is a transcription factor that regulates immune and inflammatory responses. Our laboratory has shown that normal and malignant B cells, including multiple myeloma, express PPARgamma. Moreover, certain PPARgamma ligands can induce apoptosis in multiple myeloma cells. Because PPARgamma ligands can also have PPARgamma-independent effects, the role of PPARgamma in B-cell malignancies remains poorly understood. To further understand the role of PPARgamma, we examined the functional consequences of its overexpression in humanmultiple myeloma. EXPERIMENTAL DESIGN: In the present work, we developed a lentiviral vector for PPARgamma gene delivery. We transduced multiple myeloma cells with a lentivirus-expressing PPARgamma and studied the involvement of this receptor on cell growth and viability. RESULTS:PPARgamma overexpression decreased multiple myeloma cell proliferation and induced spontaneous apoptosis even in the absence of exogenous ligand. These PPARgamma-overexpressing cells were dramatically more sensitive to PPARgamma ligand-induced apoptosis compared with uninfected or LV-empty-infected cells. Apoptosis was associated with the down-regulation of antiapoptotic proteins X-linked inhibitor of apoptosis protein and myeloid cell leukemia-1 as well as induction of caspase-3 activity. Importantly, PPARgamma overexpression-induced cell death was not abrogated by coincubation with bone marrow stromal cells (BMSC), which are known to protect multiple myeloma cells from apoptosis. Additionally, PPARgamma overexpression in multiple myeloma or BMSC inhibited both basal and multiple myeloma-induced interleukin-6 production by BMSC. CONCLUSIONS: Our results indicate that PPARgamma negatively controls multiple myeloma growth and viability in part through inhibition of interleukin-6 production by BMSC. As such, PPARgamma is a viable therapeutic target in multiple myeloma.
Authors: Robert Jaster; Philipp Lichte; Brit Fitzner; Peter Brock; Anne Glass; Thomas Karopka; Lothar Gierl; Dirk Koczan; Hans-Jürgen Thiesen; Gisela Sparmann; Jörg Emmrich; Stefan Liebe Journal: J Cell Mol Med Date: 2005 Jul-Sep Impact factor: 5.310
Authors: Denise M Ray; Kimberly M Morse; Shannon P Hilchey; Tatiana M Garcia; Raymond E Felgar; Sanjay B Maggirwar; Richard P Phipps; Steven H Bernstein Journal: Exp Hematol Date: 2006-09 Impact factor: 3.084
Authors: Patrick J Hayden; Constantine S Mitsiades; Kenneth C Anderson; Paul G Richardson Journal: Curr Opin Hematol Date: 2007-11 Impact factor: 3.284
Authors: Peter M Voorhees; Qing Chen; Deborah J Kuhn; George W Small; Sally A Hunsucker; John S Strader; Robert E Corringham; Mohamed H Zaki; Jeffrey A Nemeth; Robert Z Orlowski Journal: Clin Cancer Res Date: 2007-11-01 Impact factor: 12.531
Authors: Timothy R Rosean; Van S Tompkins; Guido Tricot; Carol J Holman; Alicia K Olivier; Fenghuang Zhan; Siegfried Janz Journal: Immunol Res Date: 2014-08 Impact factor: 2.829
Authors: Patricia J Simpson-Haidaris; Kathryn E Seweryniak; Sherry L Spinelli; Tatiana M Garcia-Bates; Thomas I Murant; Stephen J Pollock; Patricia J Sime; Richard P Phipps Journal: J Biotechnol Date: 2010-10-01 Impact factor: 3.307
Authors: Kye-Im Jeon; Ajit Kulkarni; Collynn F Woeller; Richard P Phipps; Patricia J Sime; Holly B Hindman; Krystel R Huxlin Journal: Am J Pathol Date: 2014-03-17 Impact factor: 4.307
Authors: P J Simpson-Haidaris; S J Pollock; S Ramon; N Guo; C F Woeller; S E Feldon; R P Phipps Journal: PPAR Res Date: 2010-02-28 Impact factor: 4.964
Authors: Sesquile Ramon; Simona Bancos; Thomas H Thatcher; Thomas I Murant; Safiehkhatoon Moshkani; Julie M Sahler; Andrea Bottaro; Patricia J Sime; Richard P Phipps Journal: J Immunol Date: 2012-10-05 Impact factor: 5.422
Authors: Tatiana M Garcia-Bates; Scott A Peslak; Carolyn J Baglole; Sanjay B Maggirwar; Steven H Bernstein; Richard P Phipps Journal: Cancer Immunol Immunother Date: 2008-11-19 Impact factor: 6.968